Hims & Hers Health, Inc. · 2026 Q2
ReportedAug 10, 2026
Period endedJun 30, 2026
Rule of 40+30
Consensus vs reported
EPS
MISS -640%
-$0.37
vs -$0.05 expected
QoQ+7.5%
YoY—
Revenue
BEAT +9%
$753M
vs $690.2M expected
QoQ+23.9%
YoY+38.2%
QoQ and YoY are measured on the same basis as each panel's own consensus, so no panel compares two different measures.
Reported this quarter
Revenue
$753M
QoQ +23.9%
YoY +38.2%
EPS
-$0.37
QoQ +7.5%
YoY —
Free Cash Flow
-$62M
QoQ —
YoY +5.1%
Gross Margin
63.8%
QoQ -1.4 pp
YoY -12.6 pp
FCF Margin
-8.2%
QoQ -18.0 pp
YoY +3.7 pp
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
What we learned
- The growth floor was found, hard, and it is not domestic. Revenue +38.2% after four straight decelerations that ended at +3.8%. Most of the increase is not US.
- The loss repeated, so it is a trend. −$0.37 after −$0.40, and a $86.3M loss against $42.5M of net income a year earlier. Two consecutive losses is no longer an event.
- Free cash flow swung exactly as the preview said it might. −$61.9M, a −8.2% margin , from the 9.8% we called "volatile, not durably positive".
- "Updates" was the word doing the work in the guidance headline. Revenue guidance was raised to $3.1–3.3B; Adjusted EBITDA was updated from $275–350M — a cut disguised as an update by one verb.
- The legal overhang got a number, not an answer. $47.5M of legal contingencies booked in the quarter and $62.5M for the half, with the release not saying which matter it relates to.
Read the full analysis: Hims Got Its Growth Back. The Profit Guidance Went Down. →
Coverage around this release
R40
Hims's Cancer Test Costs $699, Not the $250 We Printed in February. WHOOP Now Sells the Same Test for $799 With No Subscription at All.
News · Aug 20, 2026
R40
Hims Got Its Growth Back. The Profit Guidance Went Down.
News · Aug 11, 2026
R40
We Covered Hims Four Times in Eight Days, Then Went Quiet for Six Months. It Reports Monday.
News · Aug 1, 2026
Estimate against reported
Our published estimate
Reported EPS
Average surprise -456% over 3 graded quarters
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| 2024 Q3 | — | $0.32 | — |
| 2024 Q4 | — | $0.11 | — |
| 2025 Q1 | — | $0.20 | — |
| 2025 Q2 | — | $0.17 | — |
| 2025 Q3 | $0.09 | $0.06 | -33% |
| 2025 Q4 | $0.04 | $0.08 | +100% |
| 2026 Q1 | $0.03 | -$0.40 | -1433% |
| 2026 Q2 | -$0.05 | -$0.37 | -640% |
Estimates are the consensus we published on our own preview for that quarter; quarters we did not preview carry the reported figure only. Where a consensus was set on a non-GAAP basis, the reported column shows that same measure.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1773751.
JSON
Company facts (XBRL)
Every figure HIMS has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for 2026 Q2, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings